Compare Revvity Inc (RVTY) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Teladoc Health Inc — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Teladoc Health Inc trades at $6.09 (market cap $1.14B). The key difference: Revvity Inc is far larger — about 12.4× Teladoc Health Inc's market cap, and Revvity Inc pays a 0.22% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| RVTY | TDOC | |
|---|---|---|
Market Cap | $14.18B | $1.14B |
Sector | Technology | Health |
52-Week High | $130.94 | $9.72 |
52-Week Low | $82.26 | $4.47 |
Enterprise Value | $16.50B | $1.40B |
Dividend Yield | 0.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Recent news includes the appointment of a new CFO and ongoing legal investigations, while analyst consensus is a $8.88 price target with a hold-heavy rating.
The outlook is mixed: valuation metrics like P/S of 0.45 and EV/EBITDA of 6.5 suggest potential undervaluation, but persistent losses and negative cash flow in 2025 pose risks. Upside hinges on profitability improvements from its integrated care segment, while competitive pressures and weak BetterHelp performance are headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
